Skip to content

Medical-device intelligence

NIG: System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer

FDA product code NIG: System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
NIG
FDA device name
System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer
Device class
2
Regulation number
866.6010
Medical specialty
Immunology
Review panel
IM

FDA definition

An in vitro diagnostic test for the quantitative measurement of the CA 19-9 tumor associated antigen in human serum or plasma. The test is intended as an aid in the management of patients with confirmed pancreatic cancer and serial monitoring of their response to therapy and disease progression. The test should only be used in patients with serum and plasma CA 19-9 values above the cut-off at the time of diagnosis and in conjunction with other clinical methods.
Explore immunology records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

12 clearance records and 19 recall records in the covered releases, across 12 source company names and 1 product codes. Dated history runs from May 9, 2002 to Aug 10, 2026.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202600
February 202600
March 202600
April 202600
May 202600
June 202600
July 202600
August 202610
September 202600
October 202600

Product codes represented

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

31 matching records
Device / recordCompany in FDA recordSourceSource date
Atellica IM CA 19-9 IIK253528 · NIGSiemens Healthcare Diagnostics, Inc.510(k)Aug 10, 2026FDA decision date
Atellica IM CA 19-9 (50 Test)-In vitro diagnostic use in the quantitative measurement of the CA 19-9 tumor-associated antigen in human serum usin…Z-3100-2024 · NIGSiemens Healthcare Diagnostics, Inc.RecallSep 11, 2024FDA classification date
Atellica IM CA 19-9 (250 Test)- In vitro diagnostic use in the quantitative measurement of the CA 19-9 tumor-associated antigen in human serum us…Z-3101-2024 · NIGSiemens Healthcare Diagnostics, Inc.RecallSep 11, 2024FDA classification date
Atellica IM CA 19-9 (250 Test - REF)-In vitro diagnostic use in the quantitative measurement of the CA 19-9 tumor-associated antigen in human ser…Z-3102-2024 · NIGSiemens Healthcare Diagnostics, Inc.RecallSep 11, 2024FDA classification date
ADVIA Centaur CA 19-9 (50 Test)-In vitro diagnostic use in the quantitative measurement of the CA 19-9 tumor-associated antigen in human serum us…Z-3103-2024 · NIGSiemens Healthcare Diagnostics, Inc.RecallSep 11, 2024FDA classification date
ADVIA Centaur CA 19-9 (250 Test)-In vitro diagnostic use in the quantitative measurement of the CA 19-9 tumor-associated antigen in human serum u…Z-3104-2024 · NIGSiemens Healthcare Diagnostics, Inc.RecallSep 11, 2024FDA classification date
VITROS Immunodiagnostic Products CA 19-9TM Reagent PackK231525 · NIGOrtho Clinical Diagnostics510(k)Aug 9, 2023FDA decision date
Beckman Coulter ACCESS Immunoassay Systems, Access GI Monitor Cancer Antigen 19-9, REF 387687 ( UDI: 15099590231842) the Access Family of Immuno…Z-2241-2020 · NIGBeckman Coulter Inc.RecallJun 2, 2020FDA classification date
Lumipulse G CA19-9-NK200997 · NIGFujirebio Diagnostics,Inc.510(k)May 14, 2020FDA decision date
Elecsys CA 19-9, Cat. No. 07027028190 - Product Usage: the product is an immunoassay for monitoring and management of pancreatic cancerZ-1444-2020 · NIGRoche Diagnostics Operations, Inc.RecallMar 5, 2020FDA classification date
Lumpipulse G CA19-9-NK191973 · NIGFujirebio Dianostics, Inc.510(k)Oct 22, 2019FDA decision date
ST-AIA PACK CA 19-9; Part Number: 025271 Assay, Tumor MarkerZ-2069-2018 · NIGTosoh Bioscience IncRecallJun 5, 2018FDA record creation date
Access System-GI Monitor (CA19-9), A83873D, Catalog No. 387687Z-2638-2017 · NIGBeckman Coulter Inc.RecallJun 28, 2017FDA record creation date
ADVIA Centaur CA 19-9 Assay (50 test kit)-for use, with the ADVIA Centaur and ADVIA Centaur XP, ADVIA Centaur XPT and ADVIA Centaur CP systems. …Z-0612-2017 · NIGSiemens Healthcare Diagnostics, IncRecallNov 17, 2016FDA record creation date
ADVIA Centaur CA 19-9 Assay (250 test kit)-for use,with the ADVIA Centaur and ADVIA Centaur XP, ADVIA Centaur XPT and ADVIA Centaur CP systems. …Z-0613-2017 · NIGSiemens Healthcare Diagnostics, IncRecallNov 17, 2016FDA record creation date
VITROS Immunodiagnostic Products CA 19-9 Calibrators and Reagent Packs, Lot 1320 VITROS CA 19-9 Reagent Packs are used on VITROS ECi/ECiQ Immu…Z-2183-2014 · NIGORTHO-CLINICAL DIAGNOSTICSRecallAug 11, 2014FDA classification date
Siemens Healthcare ADVIA Centaur CA 19-9 250 Test 10491244 50 Test 10491379 Intended Use The ADVIA Centaur CA 19-9 Assay is an in vitro immunoa…Z-0508-2013 · NIGSiemens Healthcare Diagnostics, IncRecallDec 11, 2012FDA classification date
ARCHITECT CA 19-9XR Reagent Kit; ARCHITECT CA 19-9 Reagent Kit, list 291-20 (4 x 100 tests), 2K91-25 and 2K91-27 (1 x 100 tests); Product U…Z-1904-2012 · NIGAbbott LaboratoriesRecallJun 29, 2012FDA classification date
ADVIA Centaur CA19-9 Assay Cat. Nos. 123521 (03481938) - 250 Test kit w/o Calibrators 123519 (04612750) - 50 Test kit w/o Calibrators 10491244 - …Z-0489-2012 · NIGSiemens Healthcare Diagnostics, IncRecallJan 11, 2012FDA classification date
DIMENSION VISTA LOCI CA 19-9 FLEX REAGENT CARTRIDGE, AND DIMENSION LOCI7 CALIBRATOR WITH MODEL(S) K6457, AND KC604K100375 · NIGSiemens Healthcare Diagnostics, Inc.510(k)Apr 6, 2011FDA decision date
CA19-9 ELISA Kit. BioCheck, Foster City, CA 9440. Quantitative determination of AFP concentration in human serum.Z-1630-2011 · NIGBioCheck IncRecallMar 11, 2011FDA classification date
VITROS CA 19-9K052889 · NIGFujirebio Diagnostics,Inc.510(k)Dec 20, 2005FDA decision date
ARCHITECT CA 19-9XR ASSAYK052000 · NIGFujirebio Diagnostics,Inc.510(k)Oct 25, 2005FDA decision date
TOSOH brand AIA-600 II Enzyme Immunoassay Analyzer; Software version 3.12, Catalog Numbers 019359, 019400; Model 019400, Smart MediaZ-0218-05 · NIGTosoh Bioscience, Inc.RecallNov 30, 2004FDA classification date
Tosoh brand AIA-PACK CA 19-9 Test Cup Set used in TOSOH AIA Immunoassay Analyzers, A pack contains 10 trays of 20 test cups, Catalog #: 020271, F…Z-0197-05 · NIGTosoh Bioscience, Inc.RecallNov 16, 2004FDA classification date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗